Akiko Takagi
| Faculty of Pharmaceutical Sciences,Department of Pharmaceutical Sciences | Assistant Professor |
Last Updated :2025/10/07
■Researcher basic information
■Career
■Research activity information
Paper
- 日本有害事象自発報告データベースを用いた薬剤性嚥下障害の発現時期の評価(Evaluation of the time-to-onset of drug-induced dysphagia using the Japanese Adverse Drug Event Report database)
輿石 徹; 百 賢二; 濃沼 政美; 高木 彰子; 奥山 清; 中村 均
医薬品相互作用研究, Mar. 2019 - 病院薬剤師における職務満足度と勤務継続意識の関係についての検討
Oct. 2018 - 医療職資格試験におけるクリニカルパス関連問題の出題傾向の分析
Sep. 2018 - Assessment of statin-induced interstitial pneumonia in patients treated for hyperlipidemia using a health insurance claims database in Japan.
Kenji Momo; Akiko Takagi; Atsuko Miyaji; Masayoshi Koinuma
Pulmonary pharmacology & therapeutics, Jun. 2018
PURPOSE: This study aimed to determine the frequency and risk factors for statin-induced interstitial pneumonia (IP). METHOD: We conducted a retrospective cohort study using a large Japanese health insurance claims database. We determined the statin-induced IP incidence in patients treated with statins for hyperlipidemia (n = 194,814) with 12-month screening and 3-month observation periods. Statin-induced IP was defined as: (1) diagnosis with IP (ICD-10 codes: J70.2-J70.4, J84.1, and J84.9) within 3 months after starting statins; (2) steroid administration starts after starting statins; (3) undergoing laboratory tests for sialylated carbohydrate antigen Krebs von den Lungen-6 or pulmonary surfactant protein-D; and (4) undergoing high-resolution computed tomography (HRCT). Risk factors for IP were defined as presence of lung-related diseases including lung cancer and IP (ICD-10 codes: A15-16, J12-18, 43-46, 60-70, and 80-99) that were known to the risk factors inducing IP during the screening period. RESULTS: Cohort 1 had no IP-inducing risk factors; based on lung-related disease history, we identified 4 cases (male/female: 0/4, 61 ± 2.5 years) and 46,574 controls (male/female: 29,677/16,897, 51.3 ± 9.5 years). In cohort 1, all cases were female and average age was older than that of controls (p < 0.01). Cohort 2 had lung-related disease history that were known to the risk factors inducing IP; we identified 25 cases (male/female: 11/14, 52.8 ± 11.3 years) and 4005 controls (male/female: 2305/1,700, 51.0 ± 10.4 years). IP incidence was higher in cohort 2 than in cohort 1, who had no IP risk factors (0.6% vs. 0.009%, p < 0.01). The adjusted case/control odds ratio in cohort 2 was 3.8 (1.7-8.5) in patients who had taken atorvastatin and 2.5 (1.1 - 5.6) with diabetes mellitus. DISCUSSION: We clarified the incidence (0.009% and 0.6% in patients without and with lung-related disease history that were known to the risk factors inducing IP, respectively) and risk factors for statin-induced IP (elderly females without lung-related disease history; atorvastatin administration in those with lung-related disease history). Physicians and pharmacists should pay close attention to female patients starting atorvastatin, especially those with past histories of lung-related diseases that were known to the risk factors for IP. - 地域包括ケア病棟の設置に関連する因子の探索
Oct. 2015 - [Search for Factors Related to Vascular Pain Expression upon Administration of Oxaliplatin into a Peripheral Vein].
Akiko Takagi; Nao Yonemoto; Yuuya Aoyama; Yuri Touma; Michiko Kajiwara; Kosuke Watanabe; Yoshiko Miyazaki; Masayoshi Koinuma
Gan to kagaku ryoho. Cancer & chemotherapy, Jul. 2015
We investigated the relationship between vascular pain and various characteristics (age, sex, cancer stage, performance status [PS], height, weight, body mass index [BMI], body surface area, oxaliplatin dose, and presence and absence of the initial administration of dexamethasone) in colorectal cancer patients who were administered initial doses of oxaliplatin intravenously. The study population included 29 patients treated at Higashi Totsuka Memorial Hospital between June 2010 and April 2014. One-way analysis of variance showed that vascular pain was significantly associated with weight (p=0.015), body surface area (p=0.013), and oxaliplatin doses (p=0.0026), where the significance level was p=0.05. Logistic regression analysis and the likelihood ratio test demonstrated that the likelihood of vascular pain increased with the increase in the oxaliplatin dose. According to the cut-off value of vascular pain determined using the receiver operating characteristic (ROC) analysis, a single dose of oxaliplatin was determined to be 175 mg or more. According to the cut-off value established using the ROC analysis, a single dose of oxaliplatin at which vascular pain is expressed was determined to be 175 mg or more. At this dose, 13 patients complained of vascular pain and 8 did not. At doses less than 175 mg, none of the 8 patients complained of vascular pain. These results suggest that lowering the diluted concentration and reducing the infusion rate of intravenously administered oxaliplatin may reduce vascular pain. - 薬学生の患者対応不安の構造化と演習によるその変化の検討
May 2012 - 薬学生の対人能力向上を目的にした教育方法の構築と評価 アクションラーニングの活用
Nov. 2011 - 薬学生による薬学生への禁煙支援授業の実施と評価
Mar. 2011 - 実務実習事前学習の内容と学生の評価
Nov. 2010 - 「患者の語りデータベース」を活用した薬学生へのコミュニケーション教育の試み
Nov. 2010 - 薬剤師のキャリアデザイン 薬剤師のリアリティ・ショックに関する定性的分析(1)
Nov. 2009
MISC
